RT Journal Article
SR Electronic
T1 Clinical Sensitivity and Interpretation of PCR and Serological COVID-19 Diagnostics for Patients Presenting to the Hospital
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.19.20135723
DO 10.1101/2020.06.19.20135723
A1 Tyler E. Miller
A1 Wilfredo F. Garcia Beltran
A1 Adam Z. Bard
A1 Tasos Gogakos
A1 Melis N. Anahtar
A1 Michael Gerino Astudillo
A1 Diane Yang
A1 Julia Thierauf
A1 Adam S. Fisch
A1 Grace K. Mahowald
A1 Megan J. Fitzpatrick
A1 Valentina Nardi
A1 Jared Feldman
A1 Blake M. Hauser
A1 Timothy M. Caradonna
A1 Hetal D. Marble
A1 Lauren L. Ritterhouse
A1 Sara E. Turbett
A1 Julie Batten
A1 Nicholas Zeke Georgantas
A1 Galit Alter
A1 Aaron G. Schmidt
A1 Jason B. Harris
A1 Jeffrey A. Gelfand
A1 Mark C. Poznansky
A1 Bradley E. Bernstein
A1 David N. Louis
A1 Anand Dighe
A1 Richelle C. Charles
A1 Edward T. Ryan
A1 John A. Branda
A1 Virginia M. Pierce
A1 Mandakolathur R. Murali
A1 A. John Iafrate
A1 Eric S. Rosenberg
A1 Jochen Lennerz
YR 2020
UL http://medrxiv.org/content/early/2020/06/20/2020.06.19.20135723.abstract
AB Introduction The diagnosis of COVID-19 requires integration of clinical and laboratory data. SARS-CoV-2 diagnostic assays play a central role in diagnosis and have fixed technical performance metrics. Interpretation becomes challenging because the clinical sensitivity changes as the virus clears and the immune response emerges. Our goal was to examine the clinical sensitivity of two most common SARS-CoV-2 diagnostic test modalities, polymerase chain reaction (PCR) and serology, over the disease course to provide insight into their clinical interpretation in patients presenting to the hospital.Methods A single-center, retrospective study. To derive clinical sensitivity of PCR, we identified 209 PCR-positive SARS-CoV-2 patients with multiple PCR test results (624 total PCR tests) and calculated daily sensitivity from date of symptom onset or first positive test. To calculate daily clinical sensitivity by serology, we utilized 157 PCR- positive patients with a total of 197 specimens tested by enzyme-linked immunosorbent assay for IgM, IgG, and IgA anti-SARS-CoV-2 antibodies.Results Clinical sensitivity of PCR decreased with days post symptom onset with >90% clinical sensitivity during the first 5 days after symptom onset, 70-71% from days 9-11, and 30% at day 21. In contrast, serological sensitivity increased with days post symptom onset with >50% of patients seropositive by at least one antibody isotype after day 7, >80% after day 12, and 100% by day 21.Conclusion PCR and serology are complimentary modalities that require time- dependent interpretation. Superimposition of sensitivities over time indicate that serology can function as a reliable diagnostic aid indicating recent or prior infection.Competing Interest StatementDr. Gelfand reports personal fees from Henry Schein Inc., outside the submitted work; Dr. Turbett reports grants from Centers for Disease Control and Prevention, outside the submitted work; Dr. Anahtar reports personal fees and other from Day Zero Diagnostics, outside the submitted work; Dr. Ryan reports grants from CDC, during the conduct of the study.Funding StatementThis work is supported by NIH (RO1 CA225655) to J.K.L, Centers for Disease Control and Prevention U01CK000490 (E.T.R., R.C.C.), NIGMS training grant T32 GM007753 (B.M.H., T.M.C), NIH R01 AI146779 (A.G.S.). The authors nor the study received any financial support from a third-party commercial company for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Massachusetts General Hospital Institutional Review Board, 2020P000895All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified, raw data can be provided by request.